What one share of Vivos Therapeutics holds
Vivos Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.50 |
|---|---|
| Profit | −$1.84 |
| Capex (buildings and equipment) | $0.14 |
| Free cash flow | −$1.37 |
| Cash and investments | $0.12 |
| Debt | $0.57 |
| Book value | −$0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $23.10 | −$23.83 | $0.36 | −$11.18 | — | −$5.91 |
| 2020 | $25.38 | −$34.94 | $0.23 | −$11.27 | — | $23.23 |
| 2021 | $19.88 | −$23.89 | $2.82 | −$21.35 | — | $27.75 |
| 2022 | $17.41 | −$25.90 | $1.00 | −$22.28 | — | $5.22 |
| 2023 | $11.32 | −$11.14 | $0.66 | −$10.46 | — | $0.22 |
| 2024 | $2.99 | −$2.22 | $0.11 | −$2.64 | — | $1.35 |
| 2025 | $1.70 | −$2.07 | $0.23 | −$1.71 | — | −$0.16 |
Common questions about Vivos Therapeutics
How much does one share of Vivos Therapeutics earn?
Over the last 12 months, Vivos Therapeutics lost $1.84 for each share on $1.50 of sales.
Does Vivos Therapeutics pay a dividend?
Vivos Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Vivos Therapeutics’s book value per share?
Vivos Therapeutics’s book value is negative (−$0.26 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Vivos Therapeutics have?
Each share of Vivos Therapeutics has $0.12 of cash and investments and $0.57 of debt, as of June 30, 2026.
What is Vivos Therapeutics’s free cash flow per share?
−$1.37 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Vivos Therapeutics bought back shares?
Vivos Therapeutics’s share count rose about 1983% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.